This episode discusses the urgent need for more effective and tolerable therapies for patients with EGFR-mutated NSCLC who have exhausted targeted treatments, comparing the clinical benefits of a targeted ADC approach vs chemotherapy, with a focus on the TROPION-Lung01 study of Dato-DXd vs docetaxel for heavily pretreated advanced/metastatic NSCLC with actionable genomic alterations.
Please briefly discuss the urgent need for more effective and tolerable therapies for patients with EGFR-mutated NSCLC who have exhausted available, targeted therapies.
What are the clinical benefits of a targeted ADC approach vs chemotherapy for heavily pretreated advanced/metastatic NSCLC?